There are different ways to produce IgG.
One is using intact IgG from blood/plasma donors. The other one is using genetically engineered/recombinant methods which use yeast cell as host.
Which one is better? What are the ads/disads? Which one is more common? and why?
I would appreciate it if you could refer me to some helpful papers.
I am not sure what you want to use the IgG for, but if it is intended for human application, the recombinant version is clearly preferable, as you can avoid viral contaminants.
There are many companies performing production of mAbs and the process details necessary to keep the product clean is well known. Since mAbs are almost all produced by the same method, with only minor changes, check the literature for mAb production. There are tons of papers and books out there, as this is a major industry.
Achim Recktenwald but I believe the cost of mAb is much more than the intact methods? Is that why the non-recombinant methods are not that common?
I think the viral danger is the main one. Look up the many lawsuits against health authorities by patients dependent on products purified from blood getting infected with Hepatitis C, even HIV, etc. This was an the 80'is to 00-years. People went to prison.
Therefore., I do not know of any IgG still purified from plasma and used as drug. Even the enzymes, like clotting factors, are all recombinant by now.
IgG manufacturing, while not really necessary, is often done aseptically by now. The safety factor is overriding.
Besides, the production costs are only a minor part of the cost for a final drug product sold in pharmacies.
Achim Recktenwald But recombinant methods still needs purifying. right? cause there might be other proteins beside IgGs. And I didn't know companies are utilizing recombinant methods nowadays. Could you refer me to their webpages or related papers?
Yes, there are many host cell proteins and DNA, but also process-related impurities, like media components, to remove. But this is a minor problem compared ot purifying antibodies from plasma. With plasma you will always have a polyclonal mixture, while this is not the case for monoclonals.
Manufacturing mAbs, this is a major industry and the main part of the current biologics efforts. There are thousands of biotech companies looking to develop their mAb drug(s). If they sell the rights to it to a big pharma player, the drug may be manufactured by these in-house, but many land with contract manufacturing organizations (CMO), who often do also the development of the drug (CDMO). Just google for these acronyms and you will find dozens or more.
Hello Mohammad, I just received your message, but Research Gate does not allow me to answer you. When I press the Reply button, nothing happenes,
I will try again early next week, as I will be off work for a few days.
depends on what do you want to make and why.
It is not possible to make polyclonal Ig that reflected wide antigen specificities by molecular biology. A mono-clonal possibly, but, I thought cellular hybrids still commonly used for the purpose
- Badges
- Science topic
- Similar topics
- Biological Science
- Molecular Biology
- Biomolecules
- Proteins